Emergency Task Force (ETF) recommendations

The European Medicines Agency's (EMA) Emergency Task Force (ETF) makes available a list of scientific recommendations on the use of medicines.

For more information on the ETF, see:

• Emergency Task Force (ETF).

Scientific advice

Guidance for applicants: the ETF scientific advice that facilitates clinical trial authorisations (SA-CTA)

Reference Number: EMA/47386/2025

Seasonal influenza

Replacement of quadrivalent seasonal influenza vaccines with trivalent vaccines in the EU

Reference Number: EMA/123036/2024

COVID-19

EMA recommendation to update the antigenic composition of authorised COVID-19 vaccines for 2026-2027

Reference Number: EMA/127531/2026

EMA recommendation to update the antigenic composition of authorised COVID-19 vaccines for 2025-2026

Reference Number: EMA/166854/2025

ETF statement on the loss of activity of anti-spike protein monoclonal antibodies due to emerging SARS-CoV-2 variants: December 2024 update

Reference Number: EMA/571903/2024

EMA confirms its recommendation to update the antigenic composition of authorised COVID-19 vaccines for 2024-2025

Reference Number: EMA/338472/2024

EMA recommendation to update the antigenic composition of authorised COVID-19 vaccines for 2024-2025

ETF statement on use of recently updated COVID-19 vaccines

Reference Number: EMA/46094/2024

ECDC-EMA statement on updating COVID-19 vaccines composition for new SARS-CoV-2 virus variants

Reference Number: EMA/257222/2023

ETF statement on the loss of activity of anti-spike protein monoclonal antibodies due to emerging SARS-CoV-2 variants of concern

Reference Number: EMA/931457/2022

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines

ETF statement on the use of the EMA approved bivalent original / Omicron BA.4-5 mRNA vaccines for primary series

Reference Number: EMA/922920/2022

Heterologous primary and booster COVID-19 vaccination - Evidence based regulatory considerations

Reference Number: EMA/349565/2021

Mpox

ETF statement on the use of Imvanex for the prevention of mpox in children below 12 years of age

Reference Number: EMA/528419/2024

Possible use of the medicinal product TPOXX for the treatment of monkeypox

Reference Number: EMA/904994/2022

Considerations on posology for the use of the vaccine Jynneos/ Imvanex (MVA-BN) against monkeypox

Reference Number: EMA/700120/2022

Possible use of the vaccine Jynneos against infection by monkeypox virus

Reference Number: EMA/600064/2022

Chemical, biological and radio-nuclear threats used in the context of terrorism, crime or warfare

EMA guidance on the use of medicinal products for treatment and prophylaxis in case of exposure to biological agents used as weapons of terrorism, crime or warfare

Reference Number: EMA/323691/2024 Corr.

EMA guidance on the use of medicinal products for treatment in case of exposure to chemical agents used as weapons of terrorism, crime, or warfare

Reference Number: EMA/323692/2024 Corr.

Vector-borne diseases

PRAC-ETF considerations on the use of Ixchiq live attenuated virus vaccine against chikungunya

Reference Number: EMA/151849/2025

Preparedness

• EMA's Emergency Task Force (ETF) – Accelerating Clinical Trials in the European Union (ACT EU) priority action on clinical trials in public health emergencies: Workshop report (21-22/11/2024)

Page update history

An update log is available to show the date and summary of changes to this webpage. It does not include updates to linked documents or minor edits like typos or broken link fixes.

The tracking of updates begins in May 2026.

See update history

29 May 2026

'COVID-19' section updated with 'EMA recommendation to update the antigenic composition of authorised COVID-19 vaccines for 2026-2027' document.